Eris Lifesciences completes acquisition of 19% equity stake in Swiss Parenterals

12 Jun 2024 Evaluate

Eris Lifesciences has completed acquisition of 19% equity stake in Swiss Parenterals (Swiss) from the promoters of the company. Earlier, the company had acquired 51% equity stake in Swiss Parenterals. 

The acquisition of Swiss Parenterals will help company to strengthen India footprint through the launch of a domestic Injectables-focused Branded Formulations business. 

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.

Eris Lifesciences Share Price

1384.50 20.45 (1.50%)
11-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1687.55
Dr. Reddys Lab 1109.15
Cipla 1463.15
Lupin 1969.05
Zydus Lifesciences 868.25
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...